


(Download) Biosimilar Clinical Development: Scientific Considerations and New Methodologies (Chapman Hall/CRC Biostatistics Series)

Biosimilar Clinical Development: Scientific Considerations and New Methodologies (Chapman Hall/CRC Biostatistics Series)

*From Chapman and Hall/CRC
ePub | *DOC | audiobook | ebooks | Download PDF*



#2990875 in Books 2017-01-17Original language:EnglishPDF # 1 9.50 x 6.50 x .751, .0 #File Name: 1482231697268 pages | File size: 57.Mb

From Chapman and Hall/CRC : Biosimilar Clinical Development: Scientific Considerations and New Methodologies (Chapman Hall/CRC Biostatistics Series) before purchasing it in order to gage whether or not it would be worth my time, and all praised Biosimilar Clinical Development: Scientific Considerations and New

Methodologies (Chapman Hall/CRC Biostatistics Series):

Biosimilars have the potential to change the way we think about, identify, and manage health problems. They are already impacting both clinical research and patient care, and this impact will only grow as our understanding and technologies improve. Written by a team of experienced specialists in clinical development, this book discusses various potential drug development strategies, the design and analysis of pharmacokinetics (PK) studies, and the design and analysis of efficacy studies.

About the Author Dr. Kerry B. Barker is the Vice-President and Head of Early Oncology Research Statistics at Pfizer, Dr. Sandeep Menon is the Vice-President and Head of Biostatistics Research and Consulting Center at Pfizer, Dr. Ralph D'Agostino is a professor of Mathematics and Statistics at Boston University, Dr. Siyan Xu is a senior principal biostatistician at Novartis and Dr. Bo Jin is the Director of Biostatistics in Early Oncology Research at Pfizer. All have been involved with biosimilars clinical development across all regions of the world.